Alkem Laboratories: 7 Stock Signals Investors Are Watching Right Now
- September 18, 2026
- Posted by: Harsh Piplani
- Category: Market
Alkem Laboratories CMP Rs 5,348.5. 52W range Rs 5,051-5,934. Mcap Rs 63,848 crore. PE 28.97 vs sector 37.32.
Quick Answer
Alkem Laboratories stock signals right now span an earnings picture, a shareholding pattern where promoter holding stood at 51.20% as of the March 2026 quarter before easing to roughly 49.7% by June 2026, having decreased over the most recent quarter per public disclosures, and a technical setup where the stock trades close to its 52-week low of Rs 5,051. Debt to equity stands at 0.15, and valuation sits at a P/E of 28.97 against a sector average of 37.32. Corporate developments in the pharmaceuticals, branded generics and anti-infectives, India’s 5th largest domestic formulation company space add further context investors are tracking alongside these numbers. None of the seven signals here amounts to a buy or sell call on its own.
Alkem Laboratories stock signals are unusually layered right now, with the company trading at Rs 5,348.5, 9.9% below its 52-week high of Rs 5,934 and 5.9% above its 52-week low of Rs 5,051. Alkem Laboratories is a well tracked name in the pharmaceuticals, branded generics and anti-infectives, India’s 5th largest domestic formulation company space, and no single headline captures where the stock stands today.
This article does not make a buy, hold or sell call on Alkem Laboratories. It lays out seven signals investors commonly watch, each sourced from the company’s latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.
Click Here – Get Free Investment Predictions
Alkem Laboratories Stock at a Glance
Before going through each of the seven Alkem Laboratories stock signals in detail, the snapshot below sets the starting point on price, valuation and balance sheet strength.
| Metric | Value |
|---|---|
| Alkem Laboratories CMP | Rs 5,348.5 (NSE, 18 Sep 2026) |
| 52-Week High | Rs 5,934 (12 January 2026) |
| 52-Week Low | Rs 5,051 (7 September 2026) |
| Market Capitalisation | Rs 63,848 crore |
| P/E Ratio | 28.97 (Sector P/E 37.32) |
| P/B Ratio | 4.62 |
| Debt to Equity | 0.15 |
| Return on Equity | 16.66% |
1. Earnings Trend at Alkem Laboratories
Alkem Laboratories closed the latest full year with revenue of Rs 15,296 crore versus Rs 13,458 crore a year earlier, while net profit moved to Rs 2,353 crore from Rs 2,216 crore, a change of 6.2% on the year. The most recent quarter added Rs 3,893 crore in revenue, a change of 11.0% year on year, against Rs 521 crore in net profit versus Rs 668 crore a year earlier.
operating margin dipped sharply to 16.17% in the March 2026 quarter from a 24%-26% band in the prior three quarters, before recovering to 24.57% in June 2026; net profit was down close to 22% year on year that quarter even though full year FY26 profit still grew close to 6%. This is the first of the seven Alkem Laboratories stock signals worth tracking closely into the next results.
2. FII Holding in Alkem Laboratories
stood at 51.20% as of the March 2026 quarter before easing to roughly 49.7% by June 2026, having decreased over the most recent quarter per public disclosures
Where a full quarterly shareholding series is not available from the data source used here, the most reliable next step is to check the company’s latest exchange filing directly, since a single-quarter snapshot can be misleading without the trend around it.
3. Promoter Holding in Alkem Laboratories
Promoter holding in Alkem Laboratories stood at 51.20% as of the March 2026 quarter before easing to roughly 49.7% by June 2026, having decreased over the most recent quarter per public disclosures.
This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.
4. Debt Position at Alkem Laboratories
Alkem Laboratories’s debt to equity ratio stands at 0.15, versus 0.13 in FY25 a year earlier, one of the balance sheet metrics worth tracking alongside the earnings trend above. A lower or stable ratio generally gives more room to fund growth without leaning further on external borrowing, while a rising one is worth watching for its effect on finance costs.
This debt signal should be read alongside the valuation and corporate development signals below rather than in isolation, since capital raising plans can shift the picture from one quarter to the next.
5. Valuation of Alkem Laboratories Shares
At the current price, Alkem Laboratories trades at a price to earnings ratio of 28.97, a discount of close to 22.4% versus the sector average of 37.32. The price to book ratio stands at 4.62.
Whether that discount looks justified depends on the earnings trend from Signal 1 continuing, and it is one of the clearer places where the seven signals can pull in different directions at the same time.
6. Technical Trend on the Alkem Laboratories Chart
The stock closed around Rs 5,348.5, below both its 50-day moving average of about Rs 5,463 and its 200-day moving average of about Rs 5,504, a classic sign of a sustained downtrend. The 14-day RSI reads close to 52, in neutral territory. The MACD line sits above its signal line, a bullish momentum bias on the daily chart.
Over the past year the stock is currently 9.9% below its 52-week high of Rs 5,934 and 5.9% above its 52-week low of Rs 5,051. A sustained move back above the 50-day average would be an early technical sign of stabilisation.
7. Corporate Developments at Alkem Laboratories
Alkem Laboratories’ 52nd AGM approved all resolutions, including the final dividend and director reappointments, on 27 August 2026, even as the stock has traded under pressure alongside the broader pharmaceutical sector after the Trump administration announced tariffs of up to 200% on generic drug imports, a headwind also weighing on peers including Aurobindo Pharma, Sun Pharma and Cipla.
Check the Univest Screener for live fundamentals
What These Alkem Laboratories stock signals Mean Together
None of these seven signals on its own settles the debate on Alkem Laboratories. Reading them as a set, rather than picking out any single one, is the more balanced way to approach the stock right now. The earnings trend, shareholding pattern, balance sheet position, valuation, technical setup and corporate developments each add one piece of the picture, and they do not all point the same way at the same time.
Investors weighing Alkem Laboratories would do well to watch the next quarterly results for a read on where margins and profit are heading, alongside the next shareholding pattern update for any shift in FII or promoter positioning. Reading these Alkem Laboratories stock signals together, rather than in isolation, remains the more balanced approach. As with any single stock, price movements can be volatile and past trends do not guarantee future performance.
Also Read: HDFC Bank: 7 Stock Signals Investors Are Watching Right Now
Conclusion
Alkem Laboratories currently sits at the intersection of several moving parts, from earnings and shareholding to valuation and chart trend, and that is exactly what the seven signals above are meant to surface. This article does not recommend buying, holding or selling Alkem Laboratories shares, and readers should form their own view based on their own research and risk appetite.
Download the Univest iOS App or Univest Android App to track Alkem Laboratories live price and more such signal based stock research.
Disclaimer: Data and figures in this article are sourced from publicly available information and the company’s exchange filings. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Alkem Laboratories Stock Signals
Why is Alkem Laboratories share price where it is right now?
Ans. Alkem Laboratories shares are trading 9.9% below their 52-week high of Rs 5,934 and 5.9% above their 52-week low of Rs 5,051, shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.
What is Alkem Laboratories’s current FII holding?
Ans. A full quarterly FII holding series was not available for this article; check the company’s latest exchange filing directly.
Is Alkem Laboratories’s debt position a concern right now?
Ans. The debt to equity ratio stands at 0.15, versus 0.13 in FY25 a year earlier.
What is the promoter holding in Alkem Laboratories?
Ans. stood at 51.20% as of the March 2026 quarter before easing to roughly 49.7% by June 2026, having decreased over the most recent quarter per public disclosures.
Is Alkem Laboratories expensive compared to its sector?
Ans. Alkem Laboratories trades at a price to earnings ratio of 28.97 against a sector average of 37.32.
What recent corporate developments are relevant to Alkem Laboratories?
Ans. Alkem Laboratories’ 52nd AGM approved all resolutions, including the final dividend and director reappointments, on 27 August 2026, even as the stock has traded under pressure alongside the broader pharmaceutical sector after the Trump administration announced tariffs of up to 200% on generic drug imports, a headwind also weighing on peers including Aurobindo Pharma, Sun Pharma and Cipla.
What do the technical charts suggest about Alkem Laboratories right now?
Ans. The stock is trading below both its 50-day moving average of about Rs 5,463 and its 200-day moving average of about Rs 5,504, a classic sign of a sustained downtrend, with a 14-day RSI near 52 and its MACD line above its signal line, a bullish momentum bias.
Should investors buy Alkem Laboratories shares at current levels?
Ans. This article does not offer a buy, hold or sell recommendation. It lays out seven Alkem Laboratories stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.
